Aescap Life Sciences

Portfolio Advisor, M.D., Ph.D., and former Executive Chairman of SOBI AB, with extensive board and executive roles across numerous biotech companies. He has expertise in clinical trial design, regulatory affairs and business development.

Portfolio Advisor, M.D., MBA (INSEAD), and pharmaceutical executive who founded Pharmaplan and later the healthcare investment firm HealthCrest AG, investing in public and private healthcare companies across Europe, Asia, the US and Africa.

AI and data science specialist who builds AI-powered tools for due diligence, valuation and ESG reporting. He holds a Master's in Bioinformatics and Systems Biology from the University of Manchester and studied AI in healthcare at MIT.

Analyst with bachelor's and master's degrees in biotechnology from La Sapienza University of Rome and an advanced master's in financial markets from Solvay Brussels School. He previously worked in pharma consulting, co-founded biotech startup Hibernium, and worked at Newton Biocapital.

Portfolio Advisor with over twenty years in the medical department of Boehringer Ingelheim, holding regional and medical director roles across Europe, Asia and emerging markets. He holds a pharmacy degree from Utrecht and a PhD in cardiovascular pharmacology.

Portfolio Advisor trained as a surgeon specialising in gastrointestinal and thoracic surgery. He served as CEO of Surgis, an initiative establishing private clinics, and continues to practice surgery in France and the Netherlands.

Quantitative Analyst developing proprietary investment strategies combining medical, finance and AI backgrounds. He holds a BSc in Medicine from Leiden University, a master's from Cornell in machine learning for finance, and a CEMS Master's in International Management from LSE.

Head of Investor Relations responsible for reporting and onboarding of investors. He holds a Master's in Entrepreneurship in Life Sciences from VU University Amsterdam and previously spent over six years at a life-sciences financing consultancy helping biotech and medtech startups raise capital.

Alba Montoro is a Life Sciences Senior Analyst at Fenix Group International, LLC. Her work covers strategic analysis, market research, and competitive landscape evaluation within the pharmaceutical industry.

Founder and Portfolio Manager who joined Aescap at its 2005 founding and became managing/general partner in 2009, later transitioning the firm to public-market biotech investing and launching the Aescap Life Sciences fund (2016) and Aescap Genetics (2022). He has served as non-executive director at numerous biotech and diagnostics companies and previously ran consultancy United Healthcare B.V.

Senior Analyst who studied pharmaceutical sciences at Utrecht University and completed a master's in business and research at Leiden University, with academic research at the Leiden Academic Centre for Drug Research and Harvard Medical School.